FIG 2.

Outcomes of (A and B) patients with 11q23/KMT2A-rearranged T-ALL and (C and D) patients with t(4;11)/KMT2A-AFF1–rearranged B-ALL according to MRD levels at the EOI with a cutoff of 0.5% or 0.05% blasts, respectively. (A and C) 5-Year EFS; (B and D) 5-year OS. 5y-pEFS, probability of 5-year event-free survival; 5y-pOS, probability of 5-year overall survival; ALL, acute lymphoblastic leukemia; EFS, event-free survival; EOI, end of induction; MRD, minimal residual disease; OS, overall survival; SE, standard error.